2nd Annual Pharma 2020: The Future of R&D

Pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead in a highly challenging economic and technological environment. The R&D productivity has declined over the last decade despite increasing investments, and it is very difficult for pharma companies to boost their ROI. While the objectives of drug discovery don’t change, the methods and techniques by which pharmaceutical companies, biotechs and academia discover new drugs are evolving at a significant pace. Join the 2nd Annual Pharma 2020: The Future of R&D Summit, meet professionals from the best pharma companies and academia and learn about the new trends in drug discovery, explore the future promise of Artificial Intelligence and Machine Learning, listen to some case studies about innovations in High Throughput Screening, Big Data and precision medicine, targeting the Protein-Protein Interactions, scientific collaborations, and many other topics.

Do not forget to highlight the dates 26 - 28 March 2019 in your calendar and book the flight to Berlin as soon as possible. We are looking forward to meeting you in the best R&D Pharma Summit soon! 

Join us and register today

Stay on top of the latest trends

Key speakers



Associate Professor in Bioinformatics
Alastair LAWSON

Alastair LAWSON

Senior Fellow, Head of Antibody Biology


Chief Data Officer R&D


Program Director, Industry-Academia Liaison
Friedrich RIPPMANN

Friedrich RIPPMANN

Director, Global Computational Chemistry & Biology


Vice President ? Research

Key topics

  • Challenges in R&D Data Management
  • Current achievement and (near-)future promise of AI in drug discovery 
  • Targeting protein-protein interactions with small molecule drugs 
  • Machine-Learning Models for Predicting Frequent Hitter Behavior of Small Molecules 
  • Industry-Academia Collaborations - Opportunities and things to consider  
  • Antibody-enabled small molecule drug discovery 
  • Finding a needle in the haystack via High-Throughput screening approach 
  • How to overcome the R&D Productivity killers? 
  • The challenges and promise of cancer immunotherapy - Next-generation immune therapies

Who Should Attend

Members of board, C-level, Senior Vice Presidents, Vice Presidents, Directors, and Heads of departments from pharmaceutical industry involved in:

  • R&D
  • Drug Discovery
  • Drug Development
  • Computational Biology and Chemistry
  • Antibody Discovery
  • Medicinal Chemistry
  • Bioinformatics
  • Open Innovation
  • Data Science
  • High Throughput Screening
  • Early research and development
  • Innovation
  • External Innovation
  • External collaboration
  • Artificial Intelligence
  • Machine Learning
  • Translational Medicine
  • R&D Information Technology
  • R&D Analytics
  • New Technology
  • Immunology
  • In vivo, In vitro, In silico